Research location
Mannheim
Baden-Wurttemberg, Germany
Advertisement
Research activity in Mannheim
Baden-Wurttemberg, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 111 trials and 121 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mannheim
111 linked trials · page 1 of 3FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early PsychosisNCT07645443 · 2026-05-27 · 1 site observation
RECRUITING
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · 2026-04-29 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisNCT07225504 · 2025-11-11 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216 · 2025-07-14 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 2 site observations
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 2 site observations
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29 · 1 site observation
RECRUITING
German Dementia RegistryNCT07433010 · 2022-05-16 · 1 site observation
RECRUITING
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNCT05344469 · 2022-05-10 · 1 site observation
RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation
RECRUITING
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With SchizophreniaNCT03911726 · 2020-08-01 · 1 site observation
RECRUITING
Dabrafenib and/or Trametinib Rollover StudyNCT03340506 · 2018-01-26 · 1 site observation
RECRUITING
Praegnant Breast Cancer: Early/Advanced/MetastaticNCT02338167 · 2014-06-01 · 1 site observation
RECRUITING
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With ObesityNCT07417683 · 2026-03-01 · 1 site observation
NOT_YET_RECRUITING
Evaluation Study of New Compounds With Potential Use in SchizophreniaNCT00916201 · 2025-01-31 · 1 site observation
WITHDRAWN
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple SclerosisNCT06551519 · 2024-10-23 · 1 site observation
ACTIVE_NOT_RECRUITING
CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 DiabetesNCT06611930 · 2024-09-06 · 1 site observation
TERMINATED
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial TreatmentNCT06881810 · 2024-08-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood PressureNCT06428825 · 2024-08-16 · 1 site observation
COMPLETED
A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 YearsNCT06474208 · 2024-07-01 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108 · 2024-01-10 · 1 site observation
COMPLETED
Food Product for Management of Gestational DiabetesNCT05917808 · 2023-05-29 · 1 site observation
UNKNOWN
Computer-assisted Risk Evaluation in the Early Detection of Psychotic DisordersNCT05813080 · 2023-05-01 · 1 site observation
COMPLETED
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · 2023-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · 2023-02-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)NCT05665595 · 2023-01-19 · 1 site observation
TERMINATED
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other TherapiesNCT05566756 · 2022-10-28 · 1 site observation
COMPLETED
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerNCT05587296 · 2022-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple DosesNCT05491642 · 2022-09-08 · 1 site observation
COMPLETED
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeNCT05399888 · 2022-08-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · 2022-06-02 · 1 site observation
TERMINATED
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerNCT04752332 · 2021-05-10 · 1 site observation
TERMINATED
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast CancerNCT04495309 · 2021-03-05 · 1 site observation
COMPLETED
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · 2020-10-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)NCT04221945 · 2020-05-12 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068 · 2020-03-02 · 1 site observation
TERMINATED
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)NCT04191135 · 2019-12-19 · 1 site observation
TERMINATED
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)NCT03834506 · 2019-05-02 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation
COMPLETED
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseNCT03887455 · 2019-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Influence of a Liquid Oat Bran Product on Blood Glucose in Patients With Poorly Controlled Type 2 DiabetesNCT03805802 · 2019-02-04 · 1 site observation
COMPLETED
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)NCT03631784 · 2018-10-19 · 1 site observation
COMPLETED
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)NCT03553836 · 2018-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)NCT03515837 · 2018-06-29 · 1 site observation
COMPLETED
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's DiseaseNCT03352557 · 2018-05-03 · 1 site observation
TERMINATED
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of SchizophreniaNCT03382639 · 2018-01-04 · 1 site observation
COMPLETED
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With AsthmaNCT03248128 · 2017-10-20 · 1 site observation
COMPLETED
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383 · 2017-10-09 · 2 site observations
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.